These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30325199)

  • 1. GEN-1 immunotherapy for the treatment of ovarian cancer.
    Thaker PH; Borys N; Fewell J; Anwer K
    Future Oncol; 2019 Feb; 15(4):421-438. PubMed ID: 30325199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer.
    Cohen CA; Shea AA; Heffron CL; Schmelz EM; Roberts PC
    J Interferon Cytokine Res; 2016 Jan; 36(1):62-73. PubMed ID: 26430781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally.
    Fewell JG; Matar MM; Rice JS; Brunhoeber E; Slobodkin G; Pence C; Worker M; Lewis DH; Anwer K
    J Gene Med; 2009 Aug; 11(8):718-28. PubMed ID: 19507172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized Interleukin-12 for Cancer Immunotherapy.
    Nguyen KG; Vrabel MR; Mantooth SM; Hopkins JJ; Wagner ES; Gabaldon TA; Zaharoff DA
    Front Immunol; 2020; 11():575597. PubMed ID: 33178203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailor-made fibroblast-specific and antibiotic-free interleukin 12 plasmid for gene electrotransfer-mediated cancer immunotherapy.
    Kamensek U; Tesic N; Sersa G; Kos S; Cemazar M
    Plasmid; 2017 Jan; 89():9-15. PubMed ID: 27890562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer biology and immunotherapy.
    Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
    Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy of cancer based on interleukin 12.
    Sangro B; Melero I; Qian C; Prieto J
    Curr Gene Ther; 2005 Dec; 5(6):573-81. PubMed ID: 16457647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.
    Luo X; Xu J; Yu J; Yi P
    Front Immunol; 2021; 12():692360. PubMed ID: 34248988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.
    Malvicini M; Fiore E; Ghiaccio V; Piccioni F; Rizzo M; Olmedo Bonadeo L; García M; Rodríguez M; Bayo J; Peixoto E; Atorrasagasti C; Alaniz L; Aquino J; Matar P; Mazzolini G
    Mol Ther; 2015 Sep; 23(9):1444-55. PubMed ID: 26105158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity and immune suppression in human ovarian cancer.
    Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
    Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy of cancer with interleukin-12.
    Mazzolini G; Prieto J; Melero I
    Curr Pharm Des; 2003; 9(24):1981-91. PubMed ID: 12871184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.
    Ingersoll SB; Ahmad S; McGann HC; Banks RK; Stavitzski NM; Srivastava M; Ali G; Finkler NJ; Edwards JR; Holloway RW
    Mol Cell Biochem; 2015 Sep; 407(1-2):281-7. PubMed ID: 26048718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using genetically modified microvascular free flaps to deliver local cancer immunotherapy with minimal systemic toxicity.
    Dempsey MP; Hamou C; V JM; Ghali S; Jazayeri L; Grogan RH; Gurtner GC
    Plast Reconstr Surg; 2008 May; 121(5):1541-1553. PubMed ID: 18453976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
    Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
    Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy.
    Rossowska J; Anger N; Szczygieł A; Mierzejewska J; Pajtasz-Piasecka E
    J Exp Clin Cancer Res; 2018 Jun; 37(1):126. PubMed ID: 29954431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
    Zhang X; Feng J; Ye X; Yao Y; Zhou P; Chen X
    Gynecol Oncol; 2006 Dec; 103(3):848-52. PubMed ID: 16806435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.